Adenovirus infection remains an important cause of mortality after bone marrow transplantation (BMT). Currently no efficient antiviral treatment is known. Thus, testing new modalities of early diagnosis and treatment is a crucial objective. Adenovirus infection is defined by the combination of symptoms and the isolation of virus from the source of clinical symptoms. The involvement of two or more organs and the presence of virus in blood cultures define disseminated disease. Seven children with a median age of 7 years received bone marrow transplantation for leukemia. All received an unrelated graft without T cell depletion. Adenovirus was sought in blood, urine and biopsy specimens using PCR and culture. Analysis of biopsy specimens included systematic immunohistochemistry. Cidofovir treatment was initiated as soon as biopsy revealed the histopathological signs of adenovirus. Cidofovir was given at 5 mg/kg once weekly for 3 weeks then every 2 weeks. Six patients had diarrhoea and one patient had cystitis. Adenovirus infection and disseminated disease were diagnosed in four cases and three cases, respectively. In six cases, serotype A31 was isolated from gastrointestinal biopsy and in two cases serotypes B2 and C6 were detected in blood and urine. Cidofovir treatment was associated with clinical improvement of diarrhoea, cystitis and fever in five patients, in whom the virus became undetectable in cultures and PCR analyses despite the persistence of immunodeficiency. The median follow-up was 360 days after BMT (240-570). One child died of invasive aspergillosis and another of disseminated adenovirus after interruption of cidofovir therapy. Further studies in immunocompromised patients will be needed to extend these promising results concerning the role of cidofovir in adenovirus infection. Bone Marrow Transplantation (2001) 27, 621-626.
Summary:
Adenovirus infection remains an important cause of mortality after bone marrow transplantation (BMT). Currently no efficient antiviral treatment is known. Thus, testing new modalities of early diagnosis and treatment is a crucial objective. Adenovirus infection is defined by the combination of symptoms and the isolation of virus from the source of clinical symptoms. The involvement of two or more organs and the presence of virus in blood cultures define disseminated disease. Seven children with a median age of 7 years received bone marrow transplantation for leukemia. All received an unrelated graft without T cell depletion. Adenovirus was sought in blood, urine and biopsy specimens using PCR and culture. Analysis of biopsy specimens included systematic immunohistochemistry. Cidofovir treatment was initiated as soon as biopsy revealed the histopathological signs of adenovirus. Cidofovir was given at 5 mg/kg once weekly for 3 weeks then every 2 weeks. Six patients had diarrhoea and one patient had cystitis. Adenovirus infection and disseminated disease were diagnosed in four cases and three cases, respectively. In six cases, serotype A31 was isolated from gastrointestinal biopsy and in two cases serotypes B2 and C6 were detected in blood and urine. Cidofovir treatment was associated with clinical improvement of diarrhoea, cystitis and fever in five patients, in whom the virus became undetectable in cultures and PCR analyses despite the persistence of immunodeficiency. The median follow-up was 360 days after BMT (240-570). One child died of invasive aspergillosis and another of disseminated adenovirus after interruption of cidofovir therapy. Further studies in immunocompromised patients will be needed to extend these promising results concerning the role of cidofovir in adenovirus infection. Bone Marrow Transplantation (2001) 27, 621-626. Adenovirus infections are mild and self-limited in the immunocompetent host, whereas infection is often disseminated and rapidly fatal in immunocompromised patients with a mortality of about 60%. 1 The incidence of adenovirus infection is increased in allogeneic bone marrow transplantation (BMT). [2] [3] [4] The incidence is higher among recipients of unrelated or HLA mis-matched transplants due to the profound and persistent immunodeficiency. 2, 4 The common disease manifestations of adenovirus infection after BMT are acute hemorrhagic cystitis, pneumonia, liver failure and diarrhoea. 2, 5 After BMT, acute diarrhoea is a frequent event with a reported 43% incidence. 6 The two main etiologies are acute graft-versus-host disease (GVHD) and intestinal infection. 6 Their clinical presentation may be similar, which makes diagnosis more difficult.
Adenoviral infection can be diagnosed by viral isolation in a tissue culture system or by polymerase chain reaction (PCR) from urine, nasopharynx and blood. 7, 8 Morphological features and intranuclear inclusions due to adenovirus are also characteristic and can be rapidly (Ͻ24 h) observed by light microscopy and confirmed by immunohistochemistry. 9 Adenovirus types 1, 2, 4, 5, 6, 7, 7a, 11, 31, 32, 34 and 35 have been recovered from children and adults with immunodeficiency diseases, malignancies, steroid therapy, and after transplantation (BMT and solid organ transplantation). 5 No specific antiviral agent has been reported to be effective in the treatment of adenovirus infection, which is sometimes the direct cause of death. Previously known as (S)-1-[3-hydroxy-2 (phosphonylmethoxy) propyl] cytosine (HPMPC), cidofovir is a monophosphate nucleotide analogue of cytosine that inhibits viral DNA polymerase. This antiviral drug has in vitro and in vivo activity against several herpes viruses. 10, 11 The report of an in vitro effect of cidofovir on adenovirus led us to initiate a phase I/II study with cidofovir in grafted patients with adenovirus infection. 12 Seven children receiving an unrelated BMT were treated with cidofovir following early diagnosis of adenovirus infection. Clinical improvement was observed in five of them despite the persistence of profound immunodeficiency.
Patients and methods

Patients
The children (four boys, three girls, mean age 6.4 years) underwent BMT, from a serological HLA-A and B matched and DRB1 matched unrelated donor, for acute lymphoblastic leukemia (ALL, n = 6) or acute myeloblastic leukemia (AML, n = 1) ( Table 1 ). The patients were admitted between May 1998 and May 1999 to the Paediatric Haemato-Immunology Unit of Robert Debré Hospital. Patients, primary disease, conditioning regimen, site and type of adenoviral infection are given in Table 1 . All patients were treated in positive-pressure isolation rooms (for 21-35 days) and received non-absorbable oral antibiotics and a low bacteria-containing diet. On development of febrile neutropenia, patients received empiric antibiotics that included ceftazidime, vancomycin and amikacin. Two days later, empiric amphotericin B (1 mg/kg/day) was administered if fever persisted. All patients received weekly intravenous immunoglobulin and aciclovir. All patients were monitored weekly for quantification of pp65 CMV antigenaemia in peripheral blood. When CMV antigenaemia was positive, ganciclovir treatment was initiated according to a pre-emptive strategy.
GVHD prophylaxis consisted of cyclosporin A (from day −1) and methotrexate (day +1, day +3 and day +6) followed by steroid therapy after day +7. In this period of time antithymoglobulin (ATG) (day −3 to day −1) was included in the conditioning regimen for GVH prophylaxis. All patients received T cell-unmanipulated marrow.
Samples studied and immunohistochemistry
Gastrointestinal biopsy specimens from children with diarrhoea or vomiting and nausea were examined for GVHD and viral infection. In each case, one or two biopsies were immediately frozen in liquid nitrogen and the others were fixed in neutral-buffered formalin (4%), embedded in paraffin and stained with hematoxylin and eosin. At least 10 semi-serial sections from each biopsy specimen were examined. Immunohistochemical analysis for adenovirus was performed on all cases either on frozen or paraffin-embedded tissue samples using a three-stage immunoperoxidase technique with a mouse monoclonal anti-adenovirus antibody (Argène, Biosoft, clone H-60, Varilhes, France). Cryostat sections were also immunostained with the following antibodies: anti-HLA-DR, CD3, CD8, CD25 (Becton Dickinson, San Jose, CA, USA), and CMV (Argène, Biosoft, clone H-60).
Virological studies
Gastrointestinal biopsy specimens were cut into small fragments and used for viral isolation and nucleic acid extraction. For viral isolation, the human embryonic lung diploid fibroblast cell strain MRC-5 was cultured in 25 cm 2 flasks and inoculated with several biopsy fragments, then fed with maintenance medium and incubated at 35-36°C for 4 weeks exactly. When adenoviruses were recognized by their characteristic cytopathic effect, infected cells were harvested, pelleted by centrifugation, deposited on microscope slides, and fixed in acetone. Adenoviruses were identified by immunofluorescence, using a group-specific monoclonal antibody (Argène, Biosoft) and by PCR hybridization-EIA. 13 Further subgenus identification was performed using two adenovirus genus-specific primers in the VA RNA gene previously described by Kidd et al, 14 and amplification products were detected by agarose gel electrophoresis: band at 240-290 bp for one VA RNA gene (adenovirus of subgenera A, B2, F), and band at 410-520 bp for two VA RNA genes (adenovirus of subgenera B1, C, D, E). The adenovirus serotypes were then identified by neutralization tests with specific rabbit antiserum obtained from the American Type Culture Collection (Rockville, MD, USA).
Cidofovir management
Cidofovir (Vistide, Pharmacia & Upjohn, Luxembourg) is a nucleotide analogue of cytosine that is converted to an active intracellular metabolite, cidofovir diphosphate. Thus, unlike the nucleotide analogues (aciclovir and ganciclovir) cidofovir does not require viral thymidine kinase for phosphorylation by the cellular enzymes. The long intracellular half-life of the diphosphate (17-65 h) may explain the prolonged antiviral activity and the feasible intermittent administration of this drug. 11 However, its use is limited by the renal toxicity on the proximal convoluted tubule cells. Concomitant administration of probenecid is thought to reduce this side-effect by competing for cidofovir uptake. 15, 16 In our children, treatment with cidofovir was started as soon as adenovirus infection was diagnosed. The theoretical dose of cidofovir for CMV retinitis in patients with AIDS is 5 mg/kg once weekly for 2 weeks then once every 2 weeks. 10, 11 For our patients, cidofovir was administered at 5 mg/kg once weekly for 3 weeks followed by maintenance therapy at 5 mg/kg once every 2 weeks or 10 days. Each infusion of cidofovir was administered in combination with oral probenecid and intravenous saline hydration. A total dose of 2 g probenecid per 1.73 m 2 of body surface (BS) was given orally 3 h before infusion and 1 g per 1.73 m 2 was given 2 h and 8 h after the end of cidofovir infusion. Hydration consisted of 1 liter of normal saline per 1.73 m 2 of BS before infusion and 1 to 2 liters (if patients could tolerate) during or immediately after the cidofovir infusion. Urinalysis consisted of creatinine clearance and proteinuria determined before and after cidofovir infusion. The adaptation of cidofovir dose in patients is based on data published in AIDS patients for treatment of cytomegalovirus retinitis. 10 If urinalysis before cidofovir administration revealed proteinuria Ͼ2+ or creatinine clearance level (CCL) Ͻ55 ml/min, or serum creatinine Ͼ133 (mol/l), cidofovir administration was interrupted. Cidofovir dose was adapted according to CCL: from 60-90 ml/min, cidofovir was administered at half the theoretical dose, and from 90-120 ml/min at two-thirds of the theoretical dose. Cidofovir was not administered concomitantly with conventional amphotericin B, pentamidine or foscarnet.
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Results
Clinical symptoms
From May 1998 to May 1999, seven patients presented with adenovirus infection which is defined by the combination of symptoms and the isolation of virus from the source of clinical symptoms. Involvement of two or more organs and presence of virus in blood culture define disseminated adenovirus. Clinical symptoms are shown in Table 1 . Six patients had diarrhoea (Ͼ300 ml per day) at initial presentation (patients 1, 2, 3, 4, 5 and 6), four had fever (single temperature Ͼ38.5°C) (patients 1, 2, 3 and 4), three patients had evidence of cystitis (gross haematuria) (patients 2, 5 and 7), one at initial presentation and two a few weeks later. Anorexia (patients 1 and 3), erythematous maculopapular rash (patients 3 and 4 ) or conjunctivitis (patient 4) appeared within 2 weeks of isolation of adenovirus. One patient had invasive infection: pneumonia, encephalitis, nephritis, and hepatitis, which were the cause of death. All patients had elevated liver function tests.
Some patients also developed other viral infections several weeks after adenoviral infection: oral necrotic HSV1 and EBV post-transplantion lymphoproliferative disease, in patient 6, CMV infection in patients 5, 6 and 7.
Pathological findings
The early detection of adenovirus inclusions in gastrointestinal biopsies allowed early diagnosis of the adenoviral infection. In seven patients with diarrhoea, light microscopy identified the presence of epithelial cells containing inclusions in their nuclei that were characteristically amphophilic or eosinophilic (Figures 1 and 2) . Nuclear inclusions were present in one or several intestinal sites, mainly in the duodenum and the rectum and were found in the gastric mucosa in only one case. The morphological features were confirmed by immunohistochemistry using an Figure 1 showing numerous intranuclear inclusions. When the nuclear inclusions were numerous (Ͼ50 per biopsy), we observed epithelium buds on the surface or cryptic epithelium with sometimes shedding of the infected epithelial cells into the gland or intestinal lumen (asterisk). Hematoxylin and counterstained with eosin. Original magnification ×1000.
anti-adenovirus antibody (Figure 3) . In one case, adenovirus staining was found in a single epithelial cell. CMV antigens were not identified on gastrointestinal samples using an anti-CMV antibody. No histological features of GVHD were observed in biopsy specimens.
Adenovirus species and sites of isolation
In our patients, identified species were adenovirus type 31 subgenus A, type 2 subgenus B and type 6 subgenus C. Sites of viral isolation are shown in Table 1 . In six patients with diarrhoea, adenovirus A31 was isolated from gastro- intestinal biopsy. Two patients had a mixed infection with A31 and B2 (patient 5) and with A31 and C6 (patient 2). Four patients had virus isolated from more than one site. Adenovirus was isolated from a mean of 1.42 sites per patient (Table 1) : one site (gut biopsy) in three patients, two sites (gut biopsy and urine or throat) in two patients, three sites (gut biopsy, urine, and blood) in one patient and more than three sites in one patient (gut biopsy, urine, blood, cerebrospinal fluid, liver and bone marrow).
Adenovirus A31 was never isolated from blood. Culture and PCR of blood and urine identified C6 adenovirus in patient 2, A31 adenovirus from urine in patient 7 and B2 from CSF, urine and blood of patient 5.
Cidofovir treatment
Cidofovir was given immediately after histopathological diagnosis. The median duration of cidofovir therapy was 180 days in five patients (days 60-330).
Clinical safety:
The most common adverse effects of cidofovir were nephrotoxicity manifested as proteinuria and increased serum creatinine level (SCL). No other adverse effects were observed in our patients. Patients 1, 4, 6 and 7 tolerated cidofovir without renal dysfunction. Nephrotoxicity was observed after the second dose of cidofovir in patients 2, 3 and 5. Patients 2 and 3 had a CCL Ͻ60 ml/mn, cidofovir was interrupted and reintroduced 20 days later for patient 2 ( Figure 4) . Patient 5 had a CCL Ͻ40 ml/min, cidofovir was stopped at day 60 and he died at day 111 from invasive adenovirus infection ( Figure 5 ). Evaluation of renal function 360 days (240-570) after BMT revealed a normal SCL in four patients (40-60 mol/l) and an abnormal SCL (129 mol/l) in patient 2. This patient had received amphotericin B for 30 days before adenoviral diagnosis and cidofovir for 330 days (Table 2) . During maintenance therapy (cidofovir every 15 days), the clinical symptoms of adenovirus reappeared a few days before 
Figure 4
Case report of patient 2. Adenovirus was first detected in sigmoidal biopsies on D25 (adenovirus serotype 31, subgenus A). Cidofovir treatment was initiated on day 27 and discontinued after first infusion because of a CCL at 60 ml/min. Diarrhoea persisted and cystitis appeared on day 45. Adenovirus serotype 6, subgenus C was detected in urine and blood (by culture and PCR). Cidofovir was reintroduced at half the theoretical dose and after the second injection, the patient's general condition improved. Adenovirus was not isolated from blood, urine, or stool after day 57. *The patient continued to excrete adenovirus in the stool but the gut biopsy was not performed in these 2 weeks. Figure 5 Case report of patient 5, death at day 111. Adenovirus A31 was isolated on day 10 from sigmoidal biopsies. Cidofovir treatment was initiated on day 10. Cidofovir was continued for 44 days and discontinued after day 60 because of renal impairment (CCL = 40 ml/min). The patient's clinical condition worsened and adenovirus 2 subgenus B was detected by culture of sigmoidal biopsies and urine. On day 90, adenovirus B2 was detected in blood culture and CSF analysis. This patient died from disseminated adenoviral infection. Postmortem examination revealed numerous and disseminated typical viral inclusions in the liver, lungs, heart, kidneys, brain, bone marrow and throughout the gastrointestinal tract. In all organs, endothelial cells also contained INI, in particular in heart specimens and in digestive specimens. A special stain for acid-fast and fungal organisms and immunohistochemistry with anti-CMV antibody was negative.
administration of the drug in all patients (cystitis, diarrhoea, fever or vomiting). This observation prompted us to extend initial treatment of 5 mg/kg/week to 3 weeks instead of 2 and to decrease the maintenance therapy interval to 10 days instead of 15.
Patient outcome
The median time to resolution of clinical symptoms after cidofovir therapy was 15 days. Median follow-up after BMT was 360 days (240-570). Clinical improvement in diarrhoea, cystitis, and fever was observed in five patients in whom the virus became undetectable by urine and blood culture and PCR analysis ( Table 2 ). Outcomes that were favourable (patient 2) and unfavorable (patient 5) are shown in Figures 4 and 5. Bone Marrow Transplantation
Discussion
The present study reports the outcome of adenovirus infection in seven children who received a matched unrelated donor graft and were treated with cidofovir. These infections occurred in the context of profound immunodeficiency in all patients. ATG administered during the conditioning regimen contributed to the immunosuppression and the mean CD4 counts were zero at the time of adenovirus infection. Diarrhoea was the initial symptom in six cases and hemorrhagic cystitis in one. Rectal biopsies permitted early diagnosis based on histology and immunohistochemistry with a polyclonal antibody and this was confirmed by direct viral detection. These gastrointestinal biopsies may be informative when adenovirus infection is suspected even in the absence of gastrointestinal symptoms (patient 7). Serotype 31 subgenus A was recovered from all patients, suggesting an outbreak in our ward. Among the serotypes, type 31 is known to be associated with a higher case fatality rate (61%) with the involvement of different sites in BMT patients. 1 In our series gastrointestinal symptoms were predominant at least during the initial period of adenovirus infection. The two patients co-infected with a second serotype (C6 or B2) exhibited a more diffuse and disseminated infection.
The clinical management and treatment regimen of adenovirus infection in BMT patients are not well defined. No antiviral drugs are known to be effective. Neither polyclonal immunoglobulins nor ganciclovir have shown any clinical benefit in immunocompromised patients. 17, 18 Ribavirin has been reported to be useful in cases of hemorrhagic cystitis, pneumonia and gastroenteritis 19, 20 due to adenovirus in BMT patients but these findings are controversial. 21 There is some evidence to support the use of cidofovir in adenovirus infection. 12 This monophosphate nucleotide analogue of cytosine undergoes intracellular phosphorylation to its active diphosphate form and inhibits viral DNA polymerase. Cidofovir has in vitro and in vivo activity against several herpesviruses and is used for the treatment of cytomegalovirus retinitis. 10, 11 Adenovirus replication is inhibited in vitro by concentrations of cidofovir that can be reached in vivo.
Cidofovir has been successfully used for treating adenovirus cholecystitis and colitis in a patient with AIDS and after BMT. 22, 23 However, the nephrotoxicity of this drug hampers its usage especially in BMT patients treated with other nephrotoxic drugs such as cyclosporin A and amphotericin B. The high case fatality rate of adenovirus in these transplant patients, nevertheless warrants evaluation of the safety and clinical benefit of cidofovir after BMT.
Strict monitoring of renal function was performed in our patients so as to be able to adapt the dose or postpone administration of cidofovir. Combination with other nephrotoxic drugs was undertaken very cautiously or avoided. Cyclosporin A or liposomal, rather than conventional, amphotericin B were sometimes given but never both together. Under these conditions four patients received cidofovir treatment without major renal impairment. The evaluation of renal function 360 days (240-570) later in five survivors did not show abnormalities except in one patient with a SCL of 129 mol/l. The most severe renal impairment observed in one patient was in fact due to adenovirus as confirmed by autopsy. Similar complications have already been reported. 10, 11 Several lines of evidence suggest that cidofovir may have been effective in controlling adenovirus in our patients. Five patients who received the complete dosing schedule showed clinical improvement, moreover, adenovirus was no longer detected from different sites despite the protracted immunodeficiency. For patients 2, 3 and 5 it is possible to establish a parallel between the improvement of clinical symptoms, the absence of detection of virus and the administration of cidofovir, the interruption of treatment being associated with the reappearance of symptoms and detection of virus. These observations do not lend support to the argument that our clinical and virological results only reflect the natural history of adenovirus infection in these patients. Finally, it is likely that the strategy of rapid initiation of treatment may contribute to the clinical response. Our current strategy consists of monitoring adenovirus viremia by rapid culture whenever a patient with profound immunodeficiency presents some signs compatible with adenoviral infection. The early and simple rectal biopsy may also be an advantage.
The exact dosage of cidofovir remains to be determined. Pharmacological studies and the sensitivity of different adenovirus strains will need to be investigated. Large clinical studies will be required to confirm our findings which seem to offer some hope for treatment of this otherwise incurable BMT infection.
